PharmAla Biotech Logo 800 x 422.png
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
11 sept. 2024 08h55 HE | PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Awards Grant for Pilot MDMA-assisted Massed Exposure Therapy Trial MAPS, which has incubated and funded cutting-edge psychedelic research for decades, is continuing to advance our understanding of psychedelic-assisted therapiesThis study is one of the first trials...
PharmAla Biotech Logo 800 x 422.png
PharmAla Launches MDMA Clinical Trial Tool for Researchers
22 août 2024 09h07 HE | PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for...
psycanlogo.png
PsyCan Comments on FDA Decision Re: Lykos MDMA-Assisted Therapy Application
09 août 2024 18h28 HE | Psychedelics Canada
Psycan comments on USFDA's recent decision to request a third phase 3 trial prior to approval of
PharmAla Biotech Logo 800 x 422.png
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
09 août 2024 18h18 HE | PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
PharmAla Biotech Logo 800 x 422.png
PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
30 juil. 2024 08h55 HE | PharmAla Biotech
PharmAla releases a comprehensive investor update following its Q3 financial release, including highlights such as a 10x revenue increase and patent update
OptimiTM-03.jpg
Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
29 mai 2024 08h00 HE | Optimi Health Corp.
Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.
OptimiTM-03.jpg
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
22 mai 2024 08h30 HE | Optimi Health Corp.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
OptimiTM-03.jpg
Optimi Health Provides Corporate Update
10 mai 2024 08h50 HE | Optimi Health Corp.
Optimi Health provides corporate update.